Výsledky vyhledávání - "Gabriele Niemczyk"

Akademický článek

Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme – results from the non-interventional post-authorization safety study PRIMA

Autor: Juliane Klehmet, Yvonne Begus-Nahrmann, Kirsi Taipale, Gabriele Niemczyk, Karin Rehberg-Weber

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 16 (2023)

Background: Based on data from two large cohort studies, a label update became applicable for the class of interferon beta therapies in 9/2019, allowing interferons during pregnancy and breastfeeding. Objective: To assess pregnancy outcomes of women

Externí odkaz: https://doaj.org/article/51383f3942344e15b2872c75be847132

Zobrazit plný text záznamu

Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS

Autor: R. Dachsel, C. Wernsdörfer, H. Landefeld, G. Reifschneider, P. Knorn, S. Ries, S. Windhagen, P. Schicklmaier, S. Domke, Gabriele Niemczyk, A. Friedrich, M. Mäurer, H. Albrecht, Stefan Schwab

Publikováno v: European Journal of Neurology. 18:1036-1045

Background and purpose: First-line immunomodulatory treatment with interferon-beta or glatiramer acetate is accepted as effective basic therapy in patients with relapsing–remitting multiple sclerosis (RRMS). However, a considerable portion of patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4862059920dd76513cb9c152bfdcf4b
https://doi.org/10.1111/j.1468-1331.2010.03313.x

Zobrazit plný text záznamu

Interferon Beta-1a (AVONEX®) as a treatment option for untreated patients with multiple sclerosis (AXIOM): a prospective, observational study

Autor: Karin Rehberg-Weber, Colin Wernsdörfer, Gabriele Niemczyk, Christoph Kleinschnitz

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 16, Iss 7, Pp 15271-15286 (2015)
Volume 16
Issue 7
Pages 15271-15286

The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0badc05454bb86cfe67e95b6eaf6d1c
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-148487

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání